fbpx
October 5, 2022

Higher Levels of Omega-3 Linked to Better Brain Health in Midlife Higher Levels of Omega-3 Linked to Better Brain Health in Midlife

Consuming higher levels of omega-3 polyunsaturated fatty acids (PUFAs) is associated with larger hippocampal volumes and better abstract reasoning in healthy middle-aged adults, new research shows. […]
October 4, 2022

AF an Independent Risk Factor for Poor Outcomes in Ischemic Stroke AF an Independent Risk Factor for Poor Outcomes in Ischemic Stroke

The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer reviewed. Key Takeaways The study reported that […]
October 4, 2022

Bariatric Surgery May Up Risk for Epilepsy Bariatric Surgery May Up Risk for Epilepsy

Bariatric surgery may raise the risk of developing epilepsy, new research suggests. Analyzing health records, investigators compared almost 17,000 patients who had undergone bariatric surgery with more […]
October 4, 2022

QB’s Head Injury Spurs Scrutiny of NFL Concussion Protocol QB’s Head Injury Spurs Scrutiny of NFL Concussion Protocol

A high-profile NFL injury has put the spotlight back on football’s persistent concussions, which are linked to head trauma and a variety of long-lasting symptoms, and […]
October 4, 2022

Long Sleep, Turning In Early May Up Risk for Dementia Long Sleep, Turning In Early May Up Risk for Dementia

Too much sleep and time in bed (TIB) may raise the risk of developing dementia and Alzheimer’s disease (AD), new research suggests. Results from a population-based […]
September 30, 2022

CMS Spent Billions on Meds Without Confirmed Benefits OIG Says CMS Spent Billions on Meds Without Confirmed Benefits OIG Says

The Medicare and Medicaid programs spent more than $18 billion over 3 years on medications for which there was no proof of a significant clinical benefit, […]
September 29, 2022

FDA OKs Novel ALS Drug, Despite Unusual Path to Approval FDA OKs Novel ALS Drug, Despite Unusual Path to Approval

The US Food and Drug Administration (FDA) has approved sodium phenylbutyrate/taurursodiol (Relyvrio, Amylyx Pharmaceuticals), a novel drug to treat amyotrophic lateral sclerosis (ALS). The approval was […]
September 28, 2022

Positive Topline Phase 3 Data for Lecanemab in Early Alzheimer’s Positive Topline Phase 3 Data for Lecanemab in Early Alzheimer’s

Lecanemab (Eisai/Biogen), an investigational amyloid-clearing monoclonal antibody, reduced cognitive decline by 27% compared to placebo and decreased amyloid levels in the brain of adults enrolled in […]
September 27, 2022

ALS Drug Yields Meaningful Clinical Benefit, Phase 3 Data Show ALS Drug Yields Meaningful Clinical Benefit, Phase 3 Data Show

Longer-term data show that the antisense oligonucleotide tofersen (Biogen) slows functional decline in patients with amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1) gene […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0